Carmed Pharmaceuticals announced plans to expand its U.S. presence with an upcoming launch on Amazon, making its standardized carvacrol-based formulations more accessible to American consumers through one of the world's largest online retail platforms. The company's approach integrates traditional botanical knowledge with modern pharmaceutical methodology to develop formulations designed to support immune resilience, cellular health, and overall physiological balance.
The Amazon launch represents the next step in Carmed's U.S. market strategy following its initial entry, with the company aiming to provide broader access while maintaining scientific integrity and standardization. "Amazon allows us to make our formulations more accessible while maintaining our focus on scientific integrity and standardization," said Mustafa Can, Founder of Carmed Pharmaceuticals. "Our goal is to ensure that every product reflects the same level of research, consistency, and quality that defines our development process."
Carmed plans to introduce several flagship formulations through Amazon, including Vacrol® Kids Spray for children ages 4-11, S-Mix® for immune function support, Vacrol® Capsule for microbial balance, Vacrol-M® Capsule for respiratory wellness, and Omevaq-3® for cellular energy metabolism. The company emphasizes that its formulations are developed using standardized processes to ensure consistency, reproducibility, and quality control across product batches, with Vacrol® Kids Spray and S-Mix® being gluten-free, non-GMO, sugar-free, preservative-free, and halal-certified.
The company's development model is supported by ongoing research and collaboration with academic institutions, laboratories, and medical researchers focused on formulation science. In January 2026, a study published in the peer-reviewed journal Plants examined Vacrol® and S-Mix® in preclinical laboratory and in ovo models as part of broader scientific investigation into carvacrol-based formulations. Carmed emphasizes that such research reflects scientific investigation into botanical bioactivity and formulation design and is not presented as evidence that its consumer products diagnose, treat, cure, or prevent any disease.
This expansion is significant as it brings standardized botanical formulations to a mainstream retail platform, potentially increasing consumer access to products developed with pharmaceutical-level quality control. The move reflects growing consumer interest in evidence-based botanical supplements and the importance of standardization in ensuring product consistency and efficacy. By leveraging Amazon's distribution network, Carmed can reach consumers who prioritize research-backed formulations but may not have access to specialized health retailers.
"The Amazon launch is an important step in making Carmed's formulations available to a broader audience in the United States," said Ceren Can, Global Brand Director of Carmed Pharmaceuticals. "We are focused on delivering consistent, high-quality products while continuing to build awareness around our research-driven approach to formulation development." The company states that its U.S. strategy centers on building long-term credibility through scientific rigor, regulatory alignment, and consistent product quality as it expands distribution channels.
Availability timelines and product listings on Amazon will be announced in the coming weeks, marking a key milestone in Carmed's strategy to enable broader consumer access while supporting continued investment in research and formulation development. The company maintains a website where consumers can find additional information about their products and scientific approach.
